JP2009533433A - ピルビン酸アルキルエステルを含む組成物とその使用 - Google Patents

ピルビン酸アルキルエステルを含む組成物とその使用 Download PDF

Info

Publication number
JP2009533433A
JP2009533433A JP2009505389A JP2009505389A JP2009533433A JP 2009533433 A JP2009533433 A JP 2009533433A JP 2009505389 A JP2009505389 A JP 2009505389A JP 2009505389 A JP2009505389 A JP 2009505389A JP 2009533433 A JP2009533433 A JP 2009533433A
Authority
JP
Japan
Prior art keywords
composition
pyruvate
effective amount
ingesting
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009505389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009533433A5 (cg-RX-API-DMAC7.html
Inventor
アレクサンダー，ランヤ，エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2009533433A publication Critical patent/JP2009533433A/ja
Publication of JP2009533433A5 publication Critical patent/JP2009533433A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2009505389A 2006-04-12 2007-04-04 ピルビン酸アルキルエステルを含む組成物とその使用 Pending JP2009533433A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74473906P 2006-04-12 2006-04-12
PCT/US2007/008334 WO2007120544A2 (en) 2006-04-12 2007-04-04 Compositions comprising pyruvate alkyl esters and uses thereof

Publications (2)

Publication Number Publication Date
JP2009533433A true JP2009533433A (ja) 2009-09-17
JP2009533433A5 JP2009533433A5 (cg-RX-API-DMAC7.html) 2010-05-13

Family

ID=38610076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505389A Pending JP2009533433A (ja) 2006-04-12 2007-04-04 ピルビン酸アルキルエステルを含む組成物とその使用

Country Status (8)

Country Link
US (2) US20100047221A1 (cg-RX-API-DMAC7.html)
EP (1) EP2010218B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009533433A (cg-RX-API-DMAC7.html)
CN (1) CN101472613A (cg-RX-API-DMAC7.html)
AU (1) AU2007238938B2 (cg-RX-API-DMAC7.html)
CA (1) CA2683664C (cg-RX-API-DMAC7.html)
NZ (1) NZ572649A (cg-RX-API-DMAC7.html)
WO (1) WO2007120544A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046361A1 (en) * 2010-08-20 2012-02-23 American Symbolic, Llc Ethyl pyruvate compositions and methods
CN113876014B (zh) * 2021-09-06 2022-10-18 湖北中烟工业有限责任公司 一种含有烷基化甘油的雾化剂及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510357A (ja) * 1999-10-07 2003-03-18 キサンタス ライフ サイエンシズ，インコーポレイテッド ピルビン酸エステル組成物ならびに虚血および再灌流の事象後の蘇生のための使用法
JP2004528307A (ja) * 2001-03-15 2004-09-16 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法
WO2005002563A2 (en) * 2003-06-13 2005-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Eduction Method for treating alcoholic hepatitis
WO2005044299A1 (en) * 2003-10-27 2005-05-19 University Of Pennsylvania Cytoprotective effects of ethyl pyruvate
JP2005526832A (ja) * 2002-04-17 2005-09-08 クリティカル セラピューティクス，インコーポレイテッド α−ケトアルカン酸エステルまたは−アミドおよび乳酸または乳酸塩を含有する医薬組成物
WO2005094236A2 (en) * 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158057A (en) * 1975-03-28 1979-06-12 Stanko Ronald T Prevention of the accumulation of fatty deposits in the liver
GB1603724A (en) * 1977-05-25 1981-11-25 Montedison Spa Components and catalysts for the polymerisation of alpha-olefins
US4174742A (en) * 1978-02-08 1979-11-20 Murphey James D Method and apparatus for making and dispensing snow cones
US4491597A (en) 1981-01-26 1985-01-01 Scm Corporation Candy bar
US4351835A (en) 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
US4548937A (en) 1981-04-01 1985-10-22 Montefiore Hospital Method for preventing body fat deposition in mammals
US4812479A (en) * 1981-04-01 1989-03-14 The Montefiore Hospital Society Of Western Pennsylvania, Inc. Method for preventing body fat deposition in mammals
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5236712A (en) * 1988-07-29 1993-08-17 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4874790A (en) * 1988-08-15 1989-10-17 Montefiore Hospital Association Of Western Pennsylvania Method for improving the glucose metabolism of an animal having diabetic tendencies
US5134162A (en) * 1990-12-24 1992-07-28 The Montefiore Hospital Association Of Western Pennsylvania Method for lowering high blood cholesterol levels in hyperlipidemic animals and confections as the ingestion medium
US5294641A (en) 1991-11-27 1994-03-15 Montefiore - University Hospital Method for treating a medical patient for cardiac trauma
US5256597A (en) * 1992-09-04 1993-10-26 International Business Machines Corporation Self-aligned conducting etch stop for interconnect patterning
SE9303691D0 (sv) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
US5612374A (en) * 1994-02-14 1997-03-18 Ronald T. Stanko Inhibiting growth of mammary adenocarcinoma
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5621996A (en) 1995-06-07 1997-04-22 Pride Cast Metals, Inc. Combination security and display device for firearms
US5801198A (en) 1995-07-13 1998-09-01 University Of Pittsburgh Medical Center Retarding neutrophil infiltration ad morphologic reduction in ischemic bowel tissues
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6417231B1 (en) * 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
US5973005A (en) * 1998-02-26 1999-10-26 Bio-Bontanica, Inc. Aqueous creatine solution and process of producing a stable, bioavailable aqueous creatine solution
US5976550A (en) * 1998-11-20 1999-11-02 Engel; Peter H. Dietary food supplement
US6846842B2 (en) * 1999-10-07 2005-01-25 Beth Israel Deconess Medical Center, Inc. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
GB0011676D0 (en) * 2000-05-15 2000-07-05 Unilever Plc Ambient stable beverage
GB0011674D0 (en) * 2000-05-15 2000-07-05 Unilever Plc Ambient stable beverage
GB0011675D0 (en) * 2000-05-15 2000-07-05 Unilever Plc Ambient stable beverage
US20060025475A1 (en) * 2004-07-29 2006-02-02 Stanley Antosh Use of methyl pyruvate for the purpose of increasing muscle energy production.
US20100204161A1 (en) 2005-04-15 2010-08-12 Biomac Privatinstitut Fur Medizinishe Und Zahmediz Forschung, Entwicklung Und Diagnostik Gmbh Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria
US20080153897A1 (en) * 2006-09-11 2008-06-26 New Cell Formulations Ltd. Creatine pyroglutamic acid salts and methods for their production and use in individuals

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510357A (ja) * 1999-10-07 2003-03-18 キサンタス ライフ サイエンシズ，インコーポレイテッド ピルビン酸エステル組成物ならびに虚血および再灌流の事象後の蘇生のための使用法
JP2004528307A (ja) * 2001-03-15 2004-09-16 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法
JP2005526832A (ja) * 2002-04-17 2005-09-08 クリティカル セラピューティクス，インコーポレイテッド α−ケトアルカン酸エステルまたは−アミドおよび乳酸または乳酸塩を含有する医薬組成物
JP2005527592A (ja) * 2002-04-17 2005-09-15 クリティカル セラピューティクス，インコーポレイテッド α−ケトアルカン酸または−エステルもしくは−アミドを用いる腸閉塞の処置方法
WO2005002563A2 (en) * 2003-06-13 2005-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Eduction Method for treating alcoholic hepatitis
WO2005044299A1 (en) * 2003-10-27 2005-05-19 University Of Pennsylvania Cytoprotective effects of ethyl pyruvate
WO2005094236A2 (en) * 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012041705; ＭＯＳＣＩＡＮＯ，Ｇ．: 'Ｏｒｇａｎｏｌｅｐｔｉｃ　Ｃｈａｒａｃｔｅｒｉｓｔｉｃｓ　ｏｆ　Ｆｌａｖｏｒ　Ｍａｔｅｒｉａｌｓ' Ｐｅｒｆｕｍ　Ｆｌａｖｏｒｉｓｔ Ｖｏｌ．２６，　Ｎｏ．４, 2001, Ｐ．８２，８４-８５ *

Also Published As

Publication number Publication date
CN101472613A (zh) 2009-07-01
US20150157589A1 (en) 2015-06-11
NZ572649A (en) 2011-03-31
AU2007238938A1 (en) 2007-10-25
EP2010218A4 (en) 2010-05-12
CA2683664C (en) 2015-07-07
AU2007238938B2 (en) 2013-05-23
WO2007120544A2 (en) 2007-10-25
WO2007120544A3 (en) 2007-12-21
EP2010218A2 (en) 2009-01-07
CA2683664A1 (en) 2007-10-25
EP2010218B1 (en) 2018-10-10
US20100047221A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
CN102355898B (zh) 能量消耗促进剂
CN101951930A (zh) 对身体功能的恢复有用的口服或经肠组合物
JP5714227B2 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
US20150087679A1 (en) Nutritional sleep supplement
EP3590521A1 (en) Synergistic dietary supplement compositions for enhancing physical performance and energy levels
JP4739161B2 (ja) 持久力向上剤
CN102753183A (zh) 运动功能改善剂
WO2001021182A1 (fr) Agents ameliorant la resistance physique et agents favorisant l'accumulation de glycogene
JP5281268B2 (ja) 筋力向上剤
CN101296693A (zh) 持久力提高剂
JP5527986B2 (ja) 医薬組成物
TW201410238A (zh) 含有芝麻素類及γ－米糠醇及米胚芽油之組成物
JP2009533433A (ja) ピルビン酸アルキルエステルを含む組成物とその使用
AU2011300376B2 (en) Ingredients derived from Sphaeranthus indicus
JP2001269135A (ja) 体タンパク質蓄積効率を亢進する栄養組成物
JP2009209088A (ja) アスペルロシドまたはその類縁体を含む筋肉増強剤
JPWO2020091014A1 (ja) 心拍数低下剤
KR100835555B1 (ko) 기능성 초콜릿 조성물 그의 제조방법
HK1135319A (en) Compositions comprising pyruvate alkyl esters and uses thereof
CN115413787A (zh) 一种组合物及其应用
JP2014051459A (ja) 脂質代謝促進剤
HK1148944A (en) Oral or enteral composition useful for recovery of physical functions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130312